Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 30036596.
- Also identified by DOI 10.1016/j.jaci.2018.06.037 and PMC identifier 6226317.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bradykinin concentrations and the ratio of bradykinin to its stable metabolite BK1–5 (RPPGF) were significantly increased in patients presenting with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema compared to ACE inhibitor-treated controls. Cleavage of high molecular weight kininogen was not increased in patients with ACE inhibitor-associated angioedema, indicating that increased bradykinin concentrations result from decreased degradation.
Medical subject headings
- Angioedema
- Angiotensin-Converting Enzyme Inhibitors
- Bradykinin
- Peptide Fragments